Content of sP-selectin and Cytokines in Blood of Patients with Type 2 Diabetes Mellitus and Arterial Hypertension Depending on Diabetes Compensation Condition

Abstract

The goal of our research has been to study sР-selectin and cytokine content changes, namely ІL-2, ІL-6 and TNF-α in blood plasma of patients with type 2 diabetes mellitus with varying compensation for the disease and arterial hypertension, as well as to investigate a possible interrelation between sР-selectin and cytokines. To achieve the goal 137 patients with type 2 diabetes mellitus with AH of the І-ІІ stages and without AH (72 women and 65 men) have been examined. The levels of sР-selectin, ІL-2, ІL-6, TNF-α in blood serum were determined by means of immunoenzymatic assay method. As a result, a reliable increase in sP-selectin level in blood serum has been detected in patients with type 2 diabetes mellitus with deterioration of diabetes compensation along with АH; increase in ІL-6 level in groups with good and satisfactory compensation for diabetes and TNF -α in groups with bad compensation with the presence of АH. A reverse correlation between the content of sP-selectin and TNF-α in groups of those examined with non-compensated type 2 DM, associated with АH and without AH, stronger in a group of patients with type 2 DM and AH. The level of sP-selectin in blood increases with the deterioration of type 2 DM compensation along with AH. Most probable reverse correlations between sP-selectin and TNF-α levels in groups of patients with insufficient compensation for diabetes may indicate a mutually potential role of these factors in the development and progression of type 2 DM decompensation and AH.

Soluble P-Selectin Level in Patients with Deep Venous Thrombosis

“…Similarly, Hameed et al (28) found that no significant difference between sP-selectin and age, gender, smoking, arterial hypertension and hyperlipidaemia. However in other study they found that the level of sP-selectin in blood increases with deterioration of type 2 diabetes mellitus compensation and arterial Hypertension (29) . In our study patient diabetic and hypertension patient were excluded.…”

The pathogenic role of IL10 gene polymorhisms in type 1 diabetes mellitus

“…В ряде работ показано, что провоспалительные цитокины, в том числе и интерлейкин 1 (IL1), цитотоксичны для β-клеток, они участвуют в развитии эндотелиальной дисфункции, IL1 в организме запускает локальную воспалительную реакцию в ткани поджелудочной железы, а также каскад продукции других цитокинов, что в конечном счёте приводит к активации Т-и В-лимфоцитов. «Хроническая» секреция IL1 приводит к модификации Т-хелперов, которые в свою очередь активируют цито-токсические T-лимфоциты, воздействие которых приводит к необратимому разрушению β-клеток поджелудочной железы [2][3][4][5]. Прямым антагонистом IL1 c противовоспалительными свойствами и со способностью ингибировать производство воспалительных цитокинов и хемокинов является IL10, кодируемый одноимённым геном.…”